Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Company Overview - Oragenics, Inc. is a biotechnology company focused on innovative treatments for concussion and brain-related health conditions, including drug candidates for mild traumatic brain injury (mTBI) and Niemann Pick Disease Type C (NPC) [3] Financial Performance - The company filed its Annual Report on Form 10-K for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission on March 14, 2025 [1] - The audited consolidated financial statements received an unqualified audit opinion from an independent registered public accounting firm, indicating a positive assessment of the company's financial health [2] Strategic Focus - Oragenics is committed to advancing its innovative pipeline, exploring strategic opportunities, and securing necessary resources to support long-term growth [2]